Phloroglucinol in Irritable Bowel Syndrome by Jafri, Wasim et al.
Vol. 56, No. 1, January 2006 5
Original Article
Phloroglucinol in Irritable Bowel Syndrome
Wasim Jafri, Javed Yakoob, Sajjad Hussain, Nadim Jafri, Muhammad Islam
Department of Medicine, Aga Khan University Hospital, Karachi.
Abstract
Objective: To determine the efficacy and tolerability of phloroglucinol, an antispasmodic agent in the treatment
of Irritable Bowel Syndrome (IBS).
Methods: It was an open label (quasi interventional) study. One hundred patients coming to the gastroenterolo-
gy clinics of Aga Khan University Hospital with IBS as defined by the Rome II criteria were enrolled between
February 2004 and September 2004 to participate in the trial and were treated as outpatients. Phloroglucinol
(Himont) 50mg orally three times daily was given for two months. Symptoms were assessed before and during
treatment using a questionnaire.
Results: One hundred patients were enrolled in the study. Of them 61% (61/100) were males and 39% (39/100)
were females. Their mean age was 41±14 years. Sixty-eight patients completed the study and 28 dropped out.
On Phloroglucinol treatment there was an overall statistically significant improvement in abdominal pain
(p<0.001), frequency of stools per day (p<0.001), urgency (p<0.001), passage of mucus per rectum (p<0.001),
sense of incomplete defecation (p=0.001) and bloating (p=0.001). However, no response was seen in the fea-
ture of straining in both genders (p=0.676). The difference in response to treatment according to gender sepa-
rately showed statistically significant improvement in the sense of incomplete defecation in females alone
(p=0.003).
Conclusion: Phloroglucinol in a dose of 50mg three times daily is effective and well tolerated by the IBS
patients. It relieves most of the symptoms of IBS (JPMA 56:5;2006).
Introduction
Irritable bowel syndrome (IBS) is a common disor-
der which is associated with abdominal pain, bloating and
bowel habit changes characterized by loose bowels, consti-
pation or an alteration between these extremes.1 The current
consensus "Rome II criteria' define IBS as a group of func-
tional bowel disorders with two common prominent clinical
features, abdominal pain or discomfort or pain that is asso-
ciated with change in bowel habit and disordered defeca-
tion.2 The disorder affects approximately 15%-20% of the
world population and is also common in Asian countries
such as China, India, Japan and Pakistan.3-6 Although many
IBS sufferers do not seek medical care, IBS has been esti-
mated to account for 20% - 50% referrals to gastroenterolo-
gy clinics.7
The etiology and pathophysiology of IBS is multi-
factorial and no proven single etiology or effective treat-
ment has emerged. Possible abnormalities in the processing
of sensory stimuli in the "brain-gut" axis leads to the viscer-
al hypersensitivity and secondary motility change. In some
patients, a multi-factorial mechanism including stressful life
events or other psychological factors contribute consider-
ably.8-10 Among intestinal pathogens Blastocystis hominis
(B. hominis) is a unicellular protozoan found in the large
intestine of humans. Infection occurs worldwide but is com-
monly found in the tropics and developing countries.11 The
pathogenic potential of B. hominis in the human intestine is
controversial because the organism has been found in both
symptomatic and asymptomatic individuals. Currently,
there is no single therapeutic modality of proven benefit in
all IBS patients and treatment is tailored to relief of predom-
inant symptom.12 Spasmolytics are frequently effective in
relieving pain in patients with IBS.13 Among them
phloroglucinol has been used for many years and has proven
effective.14 It was shown to provide relief to abdominal
cramps together with a significant reduction in the number
and amplitude of phasic contractions by acting directly on
the colonic smooth muscle.15 This study was designed to
test the efficacy and tolerability of Phloroglucinol in the
treatment of IBS. It relieves pain and is considered to be
free of anticholinergic side effects. No toxicity has been
observed even at high doses and there is remarkable activi-
ty against pain.
Patients and Methods
It was an open label (quasi-interventional) study
investigating the effect of Phloroglucinol (Himont) 50mg
orally three times daily for two months. It was preceded by
a two weeks baseline period with no medication. One hun-
dred patients coming to the gastroenterology clinics of Aga
Khan University Hospital with IBS as defined by the Rome
II criteria (Table 1) were enrolled to participate in the trial
and were treated as outpatients. The study was approved by
the ethic review committee of the hospital. Those consent-
ing to participate were given the trial drug treatment.
Exclusion criteria were defined as all patients with colonic
disease with active parasitic infestation, inflammatory
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Table 1. The criteria used for the diagnosis of irritable bowel syn-
drome.
Rome II Symptom Criteria for IBS 
At least 12 weeks or more, which need not be consecutive, in the preced-
ing 12 months of abdominal discomfort or pain that has two out of three
features: 
1) Relieved with defecation 
2) Onset associated with a change in frequency of stool 
3) Onset associated with a change in form (appearance) of stool. 
Other symptoms that are not essential but support the diagnosis of IBS: 
(a) Abnormal stool frequency (greater than 3 bowel movements/day or less
than 3 bowel movements/week); (b) Abnormal stool form (lumpy/hard or
loose/watery stool); (c) Abnormal stool passage (straining, urgency, or
feeling of incomplete evacuation); (c) Passage of mucus (d) Bloating or
feeling of abdominal distension
Table 2. Gastrointestinal symptoms on treatment with Phloroglucinol.
Base line At 8th week end of 95% C.I. for P-value†
(n=68) treatment (n=68) Difference Difference
Abdominal Pain 65 (96%) 20 (29%) 67% 53 - 69% < 0.001
Frequency of stool (>3 per day) 39 (57%) 9 (13%) 44% 32 - 47% < 0.001
Straining 30 (44%) 27 (40%) 4% 0 - 18% 0.676
Urgency 51 (75%) 23 (34%) 41% 26 - 48% < 0.001
Sense of incomplete defecation 51 (75%) 33 (48%) 26% 12 - 35% 0.001
Mucus 34 (50%) 8 (12%) 38% 23 - 45% < 0.001
Bloating 48 (71%) 29 (43%) 28% 12 - 37% 0.001
Results are expressed as percentages, Difference of percentage and 95% Confidence Interval for difference of percentage, †p-value has been calculated through McNemar Test.
bowel disease including Crohn's disease and ulcerative coli-
tis. Baseline investigations included complete blood count
(CBC), erythrocyte sedimentation rate, stool detail report,
serum aminotransferase level (ALT), total bilirubin, creati-
nine and flexible sigmoidoscopy. Follow-up investigations
done on follow-up visit i.e. on completion of eight weeks
included CBC, creatinine and ALT. No formal sample size
calculation was done for the study and numbers depended
on the availability of patents. Informed consent was taken
from each patient before entering in the trial. Patients
recorded their symptoms in a dairy during pre-treatment and
during treatment for eight weeks period. They were called
as out-patients and symptoms were reviewed. The various
efficacy variables which were assessed are shown in Table
2.
Statistical Analysis was carried out using SPSS software.
McNamar's test was used to compare abdominal pain, fre-
quency of bowel movement more than 3 per day, straining,
urgency, sense of incomplete evacuation, passage of mucus
per rectum and bloating pre and post treatment. Results
were expressed as percentages, difference of percentage and
95% Confidence Interval for difference of percentage, †p-
value was calculated through McNamar's Test.
Results
One hundred patients were enrolled in the study. Of
them 61% (61/100) were males and 39% (39/100) females.
Their mean age was 41±14 years. Sixty-eight patients com-
pleted the study and 32 dropped out. Of these 26 patients
were stationed out of the city. Three patients had drug relat-
ed side effects with two patients experiencing new onset
headache and one allergic reaction. Three patients did not
complete the follow-up period and were excluded from the
study.  
There was relief in most of the features of IBS on
treatment with Phloroglucinol (Table 2). There was signifi-
cant improvement in abdominal pain (p<0.001), frequency
of stools per day (p<0.001), urgency (p<0.001), passage of
mucus per rectum (p<0.001), sense of incomplete defeca-
tion (p=0.001) and bloating (p=0.001) (Table 2). However,
no response was seen in the feature of straining (p=0.676)
(Tables 2 and 4).
Table 3. Gastrointestinal symptoms in male patients on treatment with Spasfon.
Base line At 8th week end of 95% C.I for P-value†
(n=40) treatment (n=40) Difference Difference
Abdominal Pain 38 (95%) 12 (30%) 65% 44 - 69% < 0.001
Frequency of stool (>3 per day) 23 (57%) 8 (20%) 37% 18 - 42% 0.007
Straining 18 (45%) 18 (45%) 0% - 0.789
Urgency 29 (72%) 17 (42%) 30% 8 - 42% 0.009
Sense of incomplete defecation 27 (67%) 20 (50%) 17% 0 - 31% 0.121
Mucus 24 (60%) 7 (17%) 42% 20 - 51% 0.005
Bloating 28 (70%) 16 (40%) 30% 8 - 42% 0.009
Results are expressed as percentages, Difference of percentage and 95% Confidence Interval for difference of percentage, †p-value has been calculated through McNemar Test.
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Table 4. Gastrointestinal symptoms in female patients on treatment with Spasfon.
Base line At 8th week end of 95% C.I. for P-value†
(n=28) treatment (n=28) Difference Difference
Abdominal Pain 27 (96%) 8 (29%) 67% 43 - 68% < 0.0001
Frequency of stool (>3 per day) 16 (57%) 1 (4%) 53% 30 - 54% 0.003
Straining 12 (43%) 9 (32%) 11% 0 - 27% 0.505
Urgency 22 (79%) 6 (21%) 57% 33 - 57% 0.002
Sense of incomplete defecation 24 (86%) 13 (46%) 39% 0 - 31% 0.003
Mucus 10 (36%) 1 (4%) 32% 7 - 38% 0.016
Bloating 20 (71%) 13 (46%) 25% 0 - 37% 0.070
Results are expressed as percentages, Difference of percentage and 95% Confidence Interval for difference of percentage, †p-value has been calculated through McNemar Test.
There was significant improvement among male
patients in abdominal pain (p<0.0001) followed by passage
of mucus, frequency of stools per day, urgency and bloating
(Table 3). Among females there was also significant
improvement in abdominal pain (p<0.0001) followed by
urgency, frequency of stool per day and sense of incomplete
defecation (Table 4).
There was an overall positive response to
Phloroglucinol in sense of incomplete defecation: however
according to gender it was only relieved significantly in
female patients (p=0.003) (Table 4).
Discussion
The establishment of a strong patient-physician rela-
tionship and reassurance form the key initial steps in the
management of IBS patient. The choice among treatment
alternatives are based on the predominant bowel habit and
on the accompanying symptom complex.  
The commonest drugs prescribed for abdominal pain
are the so called anti-spasmodics which relax smooth mus-
cle. Some such as dicyclomine and hyoscine are anticholin-
ergic whereas others e.g., mebeverine, alverine citrate have
a more direct inhibitory effect on intestinal smooth muscle.
Meta-analysis of 26 double blind trials found a significant
additional benefit for drug over placebo (average improve-
ment 64% vs 45% on placebo) but individual drug meta-
analysis failed to show a significant reduction in pain.  
This study has evaluated the effects of phlorogluci-
nol on the symptoms of IBS. The benefit of Phloroglucinol
in the management of acute episodes of IBS pain is appar-
ent and few side effects make it a good choice for patients
with chronic disorder. It is free from the anticholinergic side
effects seen in this class of agents such as constipation or
dry mouth which limits their use. There was symptomatic
relief in all features of IBS after eight weeks of treatment
with Phloroglucinol and this was consistent irrespective of
gender except sense of incomplete defecation which was
significantly relieved only in the females (Tables 2-4). In an
earlier study, mebeverine showed general clinical improve-
ment in 70% of all patients after 3 weeks of treatment.16 In
a double blind placebo controlled crossover study which
looked at the bran efficiency in IBS after three months of
therapy described a significant symptomatic improvement
compared with pretreatment in both the bran treated p<0.01
and placebo treated group p<0.01.17 Similarly this study
shows that Phloroglucinol is as effective as mebeverine and
bran in relieving IBS symptoms. This data also suggests that
Phloroglucinol had a marked beneficial effect on abdominal
pain associated with IBS. Another local study found
Phloroglucinol efficacious in relieving IBS symptoms when
compared to mebeverine though the sample size was small-
er.18 However, these results need to be confirmed with a
multicentre placebo controlled double blind study compar-
ing outcome.
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